(Benzoyl peroxide + clindamycin phosphate) is a Small Molecule owned by Bausch Health Companies, and is involved in 6 clinical trials, of which 5 were completed, and 1 is planned.
Benzoyl peroxide has anti-bacterial activity against propionibacterium acnes, the organism implicated in acne vulgaris. It has keratolytic activity and is sebostatic, counteracting the hyperkeratinisation and excessive sebum production associated with acne. Clindamycin penetrates bacteria cell wall resulting in inhibition of protein synthesis. It binds to the 50S ribosomal subunit (specifically to 23s RNA subunit) of susceptible microorganisms and inhibits the translocation of peptides thus interfering with bacterial protein synthesis. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes), an anaerobe found in sebaceous glands and follicles.
The revenue for (Benzoyl peroxide + clindamycin phosphate) is expected to reach a total of $92m through 2034. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Benzoyl peroxide + clindamycin phosphate) NPV Report.
(Benzoyl peroxide + clindamycin phosphate) is currently owned by Bausch Health Companies.
(Benzoyl peroxide + clindamycin phosphate) Overview
Benzoyl Peroxide and Clindamycin Phosphate (Benzaclin, Acanya, Onexton) is a fixed dose combination drug, an antibacterial and anti acne agent. It is formulated as gel for topical application. It is indicated for treatment of acne vulgaris.
Bausch Health Companies Overview
Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.
The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.
Quick View – (Benzoyl peroxide + clindamycin phosphate)
|Highest Development Stage|